Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma

Lamb, Yvette N.

doi:10.1007/s40265-020-01385-x

Cited by 8 publications

(2 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, daratumumab, a monoclonal antibody developed for CD38 , has been approved for the treatment of MM. 47 Our results suggested that the expression levels of SDC1 , XPO1 , TNFRSF17 , GPRC5D , and CD38 in the samples of the C1 subtype were significantly lower than those in other subtypes, while the C3 subtype showed higher expression levels of TNFRSF17 and CD38 . In summary, these observations may help physicians choose precise immune checkpoint blockade and treat patients with personalized medicine.…”

Section: Discussionmentioning

confidence: 53%

Identification of three immune molecular subtypes associated with immune profiles, immune checkpoints, and clinical outcome in multiple myeloma

Gao

Fang

et al. 2021

Cancer Medicine

View full text Add to dashboard Cite

Purpose To identify the immune molecular subtype for MM to help achieve individualized and precise targeted therapy. Methods The GDC API was used to download the TCGA‐MM profile dataset, which contains 859 samples in total, all of which were anterior to the standard treatment after diagnosis. Moreover, 282, 298, and 258 samples were stage I, stage II, and stage III separately. We used the immune gene expression profile for consistent clustering; and used the R software package ConsensusClusterPlus to sort the immune molecular subtypes. Correlation between subtypes and clinical features, immunity, and prognosis was then analyzed. Results A total of 859 tumor samples were separated into these three subtypes, which were not meaningfully related to age or sex but showed a remarkable association with stage. The results suggested that obvious differences in immune metagene expression and expression of 10 immune checkpoint genes appeared among the three subtypes. Conclusion The three subtypes are distinctly different in terms of immune metagenes, immune checkpoint molecules, and clinical prognosis. The discovery of the immune microenvironment of MM could further reveal the strategy for immunotherapy in MM and provide a promising candidate prognostic tool for survival.

show abstract

Section: Discussionmentioning

confidence: 53%

Identification of three immune molecular subtypes associated with immune profiles, immune checkpoints, and clinical outcome in multiple myeloma

Gao

Fang

et al. 2021

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…Therefore, the levels of AAG in the serum can be used as a useful predictive biomarker to identify patients that will be responsive to Arry-520 treatment. A more targeted selection of patients based on the level of AAG may increase the Arry-520 response rates possibly making Arry-520 based therapy to be equally effective as the recently developed anti-myeloma immunotherapy based on monoclonal antibodies [114]. Based on these encouraging results Arry-520 is scheduled to enter Phase III clinical trials for multiple myeloma.…”

Section: Results Of the Clinical Trialsmentioning

confidence: 99%

Eg5 targeting agents: From new anti-mitotic based inhibitor discovery to cancer therapy and resistance

Garcia-Saez

Skoufias

2021

Biochemical Pharmacology

View full text Add to dashboard Cite

Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis

Blair

2022

Drugs

View full text Add to dashboard Cite

Clinical Considerations• First-in-class CD38targeting monoclonal antibody • Associated with higher rates of haematological complete response and major organ deterioration PFS when combined with bortezomib, cyclophosphamide and dexamethasone • Acceptable tolerability profileThis plain language summary represents the opinions of the author. For a full list of declarations, including funding and author disclosure statements, please see the full text online.

show abstract

Daratumumab: A Review in Combination Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma

Cited by 8 publications

References 41 publications

Identification of three immune molecular subtypes associated with immune profiles, immune checkpoints, and clinical outcome in multiple myeloma

Identification of three immune molecular subtypes associated with immune profiles, immune checkpoints, and clinical outcome in multiple myeloma

Eg5 targeting agents: From new anti-mitotic based inhibitor discovery to cancer therapy and resistance

Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis

Contact Info

Product

Resources

About